Glimaday Tablet PR-HS is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The combination of these two agents provides complementary mechanisms of action, resulting in better control of blood glucose levels than either agent alone. Glimaday Tablet PR-HS is typically administered once daily at bedtime to optimize glycemic control and minimize gastrointestinal side effects commonly associated with Metformin. It is suitable for patients inadequately controlled on diet and exercise alone or those who have shown insufficient response to monotherapy. Regular monitoring of blood glucose, renal function, and liver function tests is recommended during therapy. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. This combination should be used as part of a comprehensive diabetes management plan, including diet, exercise, and weight control, to reduce the risk of diabetic complications.